Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease - CEA - Commissariat à l’énergie atomique et aux énergies alternatives Accéder directement au contenu
Article Dans Une Revue npj Parkinson's Disease Année : 2021

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Résumé

With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.
Fichier principal
Vignette du fichier
Oliveira et al npj Parkinson Dis 2021.pdf (1.36 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

cea-03308380 , version 1 (29-07-2021)

Identifiants

Citer

Luis M A Oliveira, Thomas Gasser, Robert Edwards, Markus Zweckstetter, Ronald Melki, et al.. Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. npj Parkinson's Disease, 2021, 7, ⟨10.1038/s41531-021-00203-9⟩. ⟨cea-03308380⟩
121 Consultations
42 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More